Tyligand Bioscience
Tyligand Bioscience is a Shanghai-based, privately held biotechnology company developing small molecule therapeutics, with its lead clinical-stage asset TSN1611, a KRAS G12D inhibitor in development for non-small cell lung cancer and other KRAS G12D-mutated malignancies.
- Company typePrivate
- Founded2018
- HeadquartersShanghai, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tyligand Bioscience does
Tyligand Bioscience is a privately held biotechnology company headquartered in Shanghai, China (3728 Jinke Rd, Building 1, West Wing), founded in 2018 with 11–50 employees. The company's stated focus is the discovery and development of small molecule therapeutics for cancer and autoimmune diseases, organized around an "efficient engine for small molecule innovation" that targets molecular mechanisms of carcinogenesis and tumor microenvironment characteristics. Its work is oriented toward regulating oncogene expression and signaling pathways, disrupting the tumor microenvironment, and restoring immune normalcy.
The company's lead clinical-stage asset is TSN1611, a KRAS G12D inhibitor being developed for KRAS G12D-mutated cancers, with non-small cell lung cancer as the primary indication. KRAS G12D is recognized as a historically difficult-to-drug oncogenic target, and TSN1611 has progressed to clinical development with data presented at the 2026 ASCO GI (Gastrointestinal Cancers Symposium) in January 2026 and at the 2026 ASCO Rapid Oral Abstract Session in May 2026. The company is led by CEO and co-founder Tony Zhang, with academic co-founder Zhong-Yin Zhang and president/co-founder Boyu Zhong completing the founding team.
Tyligand operates as a pre-commercial, pre-revenue biopharmaceutical company. Its business model centers on advancing small molecule candidates through preclinical and clinical development toward eventual regulatory approval and commercialization. To date, the company has secured capital through two funding rounds — a 2020 round led by Med-Fine Capital and a July 2023 round led by Ming Bioventures with participation from BOHE Angel Fund, CMS Capital, Calor Capital, Shengdi Investment, TaiKun Fund, and YF Capital — but no partnerships, licensing agreements, or commercial customers have been disclosed. Current external engagement is limited to scientific dissemination through oncology conference presentations and the company website.
Tyligand Bioscience firmographics
Firmographics- Name
- Tyligand Bioscience
- Legal name
- Tyligand Bioscience
- Website
- https://tyligand.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tyligand Bioscience is a Shanghai-based, privately held biotechnology company developing small molecule therapeutics, with its lead clinical-stage asset TSN1611, a KRAS G12D inhibitor in development for non-small cell lung cancer and other KRAS G12D-mutated malignancies.
- Ownership category
- akta.pro rank
Tyligand Bioscience industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industry
- Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where Tyligand Bioscience is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices1 record
Markets served
Tyligand Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Biopharmaceutical Development and Commercialization: As a pre-revenue biotech company focused on cancer therapeutic development, Tyligand generates no current revenue. The company is advancing its small molecule pipeline through research, preclinical, and clinical stages toward potential future commercialization of innovative cancer drugs.
Go-to-market motion1 record
Marketing channels1 record
Tyligand Bioscience product offering
Product offeringCore offering
Tyligand Bioscience discovers and develops small molecule therapeutics for cancer and autoimmune diseases. Its lead clinical asset is TSN1611, a novel KRAS G12D inhibitor being investigated in KRAS G12D-mutated non-small cell lung cancer and other malignancies. The company operates a small molecule innovation engine focused on oncogene signaling and tumor microenvironment modulation.
Product overview
Tyligand Bioscience is an oncology-focused biotech company developing small molecule cancer therapeutics. The company's core product is TSN1611, a KRAS G12D inhibitor currently in clinical development. The research pipeline focuses on molecular mechanisms of carcinogenesis and tumor microenvironment characteristics, targeting oncogene signaling pathways and immune restoration.
Differentiator
Problem solved
Functional benefit
Products and services
- TSN1611 TSN1611 is a proprietary small molecule KRAS G12D inhibitor in clinical development for the treatment of KRAS G12D-mutated cancers, with an initial focus on non-small cell lung cancer. It is Tyligand's primary clinical-stage therapeutic candidate and is intended for oncology patients harboring the KRAS G12D mutation.
Companies that use Tyligand Bioscience
Customer profileSegments1 record
Ideal customer profiles1 record
Tyligand Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Tyligand Bioscience partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Expansion highlights4 records
Tyligand Bioscience competitors and assessment
Company assessmentDirect peers
- Revolution Medicines: Revolution Medicines is developing RAS-targeted small molecule inhibitors including RMC-9805 (KRAS G12D), making it the most direct competitor to Tyligand's TSN1611 in the same target space, same modality, and same oncology indication.
- Mirati Therapeutics (Bristol Myers Squibb): Mirati developed MRTX1133, a clinical-stage KRAS G12D inhibitor, before being acquired by BMS; it represents the closest US-headquartered G12D competitor and a model for the BD/acquisition path Tyligand may pursue.
- Erasca: Erasca is a clinical-stage precision oncology biotech developing small molecule inhibitors against RAS/MAPK pathway targets; comparable to Tyligand in modality, stage, and oncology focus.
- Relay Therapeutics: Relay Therapeutics develops precision oncology small molecule therapies leveraging a structure-based drug design platform — sharing Tyligand's small-molecule, target-validated oncology thesis with a differentiated motion-based discovery approach.
- Tango Therapeutics: Tango is a clinical-stage small molecule oncology company targeting synthetic-lethal and oncogenic mutations; comparable to Tyligand in stage, modality, and precision-oncology focus.
Broad incumbents
- Amgen: Amgen pioneered the KRAS inhibitor space with Lumakras (sotorasib, G12C) and is investing in next-generation RAS inhibitors; a broad incumbent whose portfolio touches Tyligand's target class while operating across many therapeutic areas.
- Genentech (Roche): Genentech/Roche is a dominant oncology incumbent with active interest in KRAS and difficult-to-drug targets; representative of the large pharma partners that Tyligand may ultimately seek for co-development or commercialization.
Regional players
- HUTCHMED: HUTCHMED is a Hong Kong-headquartered clinical-stage oncology biotech with operations in China; a closely comparable China-based oncology peer in geography, stage, and commercialization aspirations.
- BeiGene: BeiGene is a leading China-founded oncology biotech with global commercialization footprint; relevant as a regional scale comparison and indicator of the pathway for Chinese oncology assets to reach global markets.
- InventisBio: InventisBio is a China-based precision oncology biotech developing targeted small molecule therapies; comparable in geography and small-molecule oncology focus, though specific oncology targets differ.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Tyligand Bioscience social profiles
Digital presenceTyligand Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tyligand Bioscience leadership team
Management profileNumber of profiles
Profiles3 records
Tyligand Bioscience funding detail
Funding detailFunding overview
Funding rounds2 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tyligand Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tyligand Bioscience
What does Tyligand Bioscience do?
Tyligand Bioscience discovers and develops small molecule therapeutics for cancer and autoimmune diseases. Its lead clinical asset is TSN1611, a novel KRAS G12D inhibitor being investigated in KRAS G12D-mutated non-small cell lung cancer and other malignancies. The company operates a small molecule innovation engine focused on oncogene signaling and tumor microenvironment modulation.
When was Tyligand Bioscience founded?
Tyligand Bioscience was founded in 2018. It employs 11 to 50 people.
Where is Tyligand Bioscience based?
Tyligand Bioscience is headquartered in Shanghai, China, in the Asia region.
How does Tyligand Bioscience make money?
One revenue line is on record: biopharmaceutical Development and Commercialization.
Who are Tyligand Bioscience's main competitors?
Direct peers on record are Revolution Medicines, Mirati Therapeutics (Bristol Myers Squibb), Erasca, Relay Therapeutics and Tango Therapeutics. Broad incumbents are Amgen and Genentech (Roche). Regional players are HUTCHMED, BeiGene and InventisBio.
Does Tyligand Bioscience have an API?
No public API is recorded for Tyligand Bioscience.
What industry is Tyligand Bioscience in?
Tyligand Bioscience's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAH, Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics). Its NAICS code is 541714 and its SIC code is 2833.